Trivedi, M. S., Shatsky, R. A., Nanda, R., Rugo, H. S., Omene, C., Kalinsky, K., … Esserman, L. (2024). LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial. In Annals of Oncology (Vol. 35, pp. S1208–S1209). Elsevier BV. https://doi.org/10.1016/j.annonc.2024.08.2253

Trivedi, M. S., R. A. Shatsky, R. Nanda, H. S. Rugo, C. Omene, K. Kalinsky, E. T. Roussos Torres, et al. “LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial.” In Annals of Oncology, 35:S1208–9. Elsevier BV, 2024. https://doi.org/10.1016/j.annonc.2024.08.2253.

Trivedi MS, Shatsky RA, Nanda R, Rugo HS, Omene C, Kalinsky K, et al. LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial. In: Annals of Oncology. Elsevier BV; 2024. p. S1208–9.

Trivedi, M. S., et al. “LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial.” Annals of Oncology, vol. 35, Elsevier BV, 2024, pp. S1208–09. Crossref, doi:10.1016/j.annonc.2024.08.2253.

Trivedi MS, Shatsky RA, Nanda R, Rugo HS, Omene C, Kalinsky K, Roussos Torres ET, Thomas B, Sanford A, Albain KS, Clark AS, Falkson CI, Isaacs C, Thomas A, Tseng J, Van’t Veer LJ, Hylton N, Yee D, Yau C, Esserman L. LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial. Annals of Oncology. Elsevier BV; 2024. p. S1208–S1209.